Open AccessLosartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients
Author(s) -
Ana Merino,
M. Antonia Álvarez-Lara,
Rafael Ramı́rez,
Julia Carracedo,
Alejandro MartínMalo,
Pedro Aljama
Publication year - 2012
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfr767
Subject(s) - losartan , medicine , cd14 , cd16 , angiotensin ii , endocrinology , pharmacology , immunology , receptor , immune system , cd8 , cd3
The principal cause of mortality in haemodialysis (HD) patients is cardiovascular disease, which is linked to chronic inflammation. Recent studies have demonstrated that angiotensin II receptor AT1 antagonists have anti-inflammatory properties. In this study, we evaluated the effect of losartan on CD14+CD16+ monocytes in HD patients. In addition, we developed an in vitro model to study the mechanisms by which losartan modulates these cells.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom